ReviewGenes & diseases2026
Lactylation-driven therapeutic resistance in cancer: Mechanisms and therapeutic opportunities.
Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Histone deacetylases in cancer metabolic reprogramming.Experimental & molecular medicine · 2026Review
- Lactate-dependent regulation of ferroptosis: redox homeostasis, lactylation, and translational perspectives.Apoptosis : an international journal on programmed cell death · 2026Review
- Histone H3K18 Lactylation Promotes the Malignant Progression of Wilms Tumor via a PSRC1/AKT/HIF-1α Positive Feedback Loop.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Machine learning-based integration identifies lactylation biomarkers for prognosis prediction and tumor microenvironment modulation in bladder cancer.Translational andrology and urology · 2026Article
- Concurrent expression of glucose-6-phosphate dehydrogenase and secreted phosphoprotein 1 characterizes an aggressive and immunosuppressive tumor state in hepatocellular carcinoma.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactylation, a type of post-translational modification (PTM) of proteins driven by cancer metabolic reprogramming, not only offers new perspectives on the Warburg effect but also has drawn increasing attention due to its critical roles in tumorigenesis and therapeutic resistance. Given its significant potential for precision cancer therapy, this review first integrates recent advancements in lactylation research by systematically summarizing newly identified lactylation writers, readers, and erasers, as well as their involvement in feedback loops and crosstalk with other modifications. Subsequently, we elaborate on how histone and non-histone lactylation contribute to both intrinsic and acquired resistance to radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Key mechanisms encompass maintaining cancer stemness, enhancing DNA damage repair, reprogramming metabolic pathways, inhibiting ferroptosis, and promoting an immunosuppressive tumor microenvironment. Finally, we evaluate preclinical strategies targeting lactylation, including inhibition of lactate metabolic pathways and direct modulation of lactylation-modifying enzymes or lactylated proteins, while critically assessing mechanistic challenges and early-phase clinical trial outcomes. Our analysis establishes a theoretical framework and actionable roadmap for the development of lactylation-based precision therapies in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.